Clinical-pathological Evaluation of Pit-NETs
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- Study ID
- NCT06607198
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Cancer
- Neuroendocrine Tumors
- Pituitary
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- grading & staging — DIAGNOSTIC_TESTTo investigate the following pathological features of PitNET cell lineage-specific transcription factors, cell type specification by hormone production, proliferative index, p53, mitotic count, expression of somatostatin receptors
- PitNET morphology analysis — DIAGNOSTIC_TESTRevision of the pre-surgical magnetic resonance images (MRIs): tumor maximum diameter, volume, sites of tumor extensions and invasion, and grading of cavernous sinus invasion
- Radiomics — DIAGNOSTIC_TESTTo investigate radiomics features of PitNETs
- Molecular test: proteomics — DIAGNOSTIC_TESTTo investigate on PitNets of molecular biomarkers Vascular Endothelial Growth Factor (VEGF), Epithelial Growth Factor Receptor (EGFR), somatostatin receptors 1-5 (SSTRs), Fibroblast Growth Factor (FGF), mTOR (mammalian target of rapamycin), Programmed cells Death 1 (PD1) and its ligands (PD-L1), and Cytotoxic T Lymphocyte Associated protein 4 (CTLA4)\]
Study Details
Pituitary adenomas, namely pituitary neuroendocrine tumors (PitNETs), are recognized as rare neoplasia by national and international institutions. Albeit most PitNETs are slow-growing with an indolent behavior, about one-third do not achieve biochemical control, recur, re-grow, and resist conventional treatments. The predictors of aggressive behavior have not been identified for PitNETs. In 2013 Trouillas and coworkers developed a five tiered clinicopathological score by mixing histopathological data and clinico-radiological evidence of invasion. This system proved of prognostic value. Nonetheless, unlike for NET of gut and lung, no formal grading and/or staging tools were developed. In addition, PitNETs have not been thoroughly investigated by radiomics to predict clinical behavior, nor have druggable pathways been elucidated in PitNET cells to unveil new potential therapeutic approaches. The first aim of this project is to define grading and staging tools for PitNETs based on: i) lineage-specific transcription factors ; ii) cell type specification by hormone production (prolactin, TSH, LH, FSH, ACTH, GH or none); iii) integration of standard radiological measures with recognized tools for clinical and pathological staging. The second aim of this project is to investigate radiomics features as predictors of PitNETs behavior, prognosis, and treatment outcome. The third aim of this project is to investigate whether the expression of molecular biomarkers \[Vascular Endothelial Growth Factor (VEGF), Epithelial Growth Factor Receptor (EGFR), somatostatin receptors 1-5 (SSTRs), Fibroblast Growth Factor (FGF), mTOR (mammalian target of rapamycin), Programmed cells Death 1 (PD1) and its ligands (PD-L1), and Cytotoxic T Lymphocyte Associated protein 4 (CTLA4)\] may impact on patients prognosis. Identifying new molecular pathways may help fine-tune and schedule the emerging targeted therapies for aggressive PitNETs, including mTOR inhibitors, VEGF, EGFR, and immune check-point inhibitors. This study will investigate a large multicenter retrospective series of 740 PitNET patients and a prospective cohort of 200 patients to reach these objectives.
Key Dates
- First listed
- Sep 23, 2024
- Start date
- Oct 1, 2024
- Status verified
- Sep 2024
- Primary completion
- Oct 1, 2026
- Completion
- Oct 1, 2026
Study Design
- Enrollment
- 940 participants (estimated)
Primary Outcome Measure
Grating and staging [ Time Frame: 2 years ]
Central Contacts
- Guido Rindi+390630154433
Find similar trials
Related Studies
- Evaluation of Late Effects and Natural History of Disease in Patients Treated With RadiotherapyRecruiting · National Cancer Institute (NCI) · Bethesda, Maryland
- Collection of Blood and Urine From Patients Undergoing Radiation TherapyEnrolling By Invitation · National Cancer Institute (NCI) · Bethesda, Maryland
- Effects of Oncological Treatment During Pregnancy on Mother and ChildRecruiting · University Hospital, Gasthuisberg · Camden, New Jersey
- Establishment of a Lifetime of Cohort of Adults Surviving Childhood CancerRecruiting · St. Jude Children's Research Hospital · Memphis, Tennessee